scholarly journals Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans

Oncogene ◽  
1998 ◽  
Vol 17 (10) ◽  
pp. 1313-1319 ◽  
Author(s):  
Angela Greco ◽  
Lisa Fusetti ◽  
Riccardo Villa ◽  
Gabriella Sozzi ◽  
Fabiola Minoletti ◽  
...  
Keyword(s):  
Growth Factor ◽  
Dermatofibrosarcoma Protuberans ◽  
Platelet Derived Growth Factor ◽  
Chain Gene ◽  
Collagen Gene ◽  
Factor B ◽  
Chimeric Sequence ◽  
Transforming Activity

Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans

2002 ◽  
Vol 20 (17) ◽  
pp. 3586-3591 ◽  
Author(s):  
Brian P. Rubin ◽  
Scott M. Schuetze ◽  
Janet F. Eary ◽  
Thomas H. Norwood ◽  
Sohail Mirza ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Imatinib Mesylate ◽  
Kinase Inhibitor ◽  
Dermatofibrosarcoma Protuberans ◽  
Response To Therapy ◽  
Platelet Derived Growth Factor ◽  
Response To Treatment ◽  
Resected Specimen ◽  
Factor B

PURPOSE: Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase. We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate. PATIENTS AND METHODS: A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid). Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomography, magnetic resonance imaging, and histopathologic and immunohistochemical evaluation. RESULTS: The patient was treated for 4 months with imatinib mesylate. The hypermetabolic uptake of FDG fell to background levels within 2 weeks of treatment, and the tumor volume shrank by over 75% during the 4 months of therapy, allowing for resection of the mass. There was no residual viable tumor in the resected specimen, indicating a complete histologic response to treatment with imatinib mesylate. CONCLUSION: Imatinib mesylate is highly active in dermatofibrosarcoma protuberans. The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.

Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma

1997 ◽  
Vol 15 (1) ◽  
pp. 95-98 ◽  
Author(s):  
Marie-Pierre Simon ◽  
Florence Pedeutour ◽  
Nicolas Sirvent ◽  
Josiane Grosgeorge ◽  
Fabiola Minoletti ◽  
...  
Keyword(s):  
Growth Factor ◽  
Giant Cell ◽  
Platelet Derived Growth Factor ◽  
Chain Gene ◽  
Collagen Gene ◽  
Β Chain
Sign in / Sign up

Export Citation Format

Share Document